Prior approval opinions of independent directors on matters related to the 12th meeting of the Fourth Board of directors
Jiangsu Chinagreen Biological Technology Co.Ltd(300970)
Independent directors’ opinions on the 12th meeting of the 4th board of directors
Prior approval opinions on matters
In accordance with relevant laws and regulations such as the company law, the guidelines for self regulation and supervision of listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, the articles of association, the working system of independent directors and other relevant provisions, and based on the principle of being responsible to the company and all shareholders, and based on independent judgment, the relevant materials submitted by the company before the 12th meeting of the Fourth Board of directors have been considered practically, They also understood and inquired about the relevant matters of the proposal. We hereby express our prior approval opinions on relevant matters as follows:
1、 Prior approval opinions on re employment of audit institutions in 2022
The independent directors of the company believe that Zhitong Certified Public Accountants (special general partnership) is qualified for securities and futures related businesses, and has many years of experience and ability to provide audit services for listed companies, which can meet the requirements of the company’s financial audit. Have independence, professional competence and investor protection ability, and be able to practice in good faith. This renewal complies with relevant laws and regulations and the relevant provisions of China Securities Regulatory Commission and Shenzhen Stock Exchange, and there is no situation that damages the interests of the company and shareholders, especially minority shareholders. Therefore, it is agreed to submit the proposal of renewing the appointment of Zhitong Certified Public Accountants (special general partnership) as the audit institution of the company in 2022 to the board of directors of the company for deliberation.
2、 Prior approval opinions of related parties on providing guarantee for the company and its subsidiaries’ application for comprehensive credit line to financial institutions in 2022
In order to ensure the capital needs of the company and its subsidiaries for business operation and development in 2022 and actively expand financing channels, the company and its subsidiaries intend to apply to financial institutions for a comprehensive credit line of no more than 400 million yuan (including this amount), and the related parties will provide joint and several liability guarantee for the company and its subsidiaries. This connected transaction is conducive to the operation and development of the company, does not affect the independence of the company, and does not damage the interests of the company and all shareholders. Agree to submit the proposal to the board of directors for deliberation.
3、 Prior approval opinions on the company’s expected daily connected transaction limit in 2022
We believe that the company expects the daily connected transaction quota in 2022 to meet the needs of the company’s business development and production and operation. There is no situation that damages the interests of the company and shareholders, which will have a positive impact on the company’s future financial situation and operating results and will not affect the independence of the company. We unanimously agree to submit the proposal on the company’s expected daily connected transaction quota in 2022 to the board of directors for deliberation.
(no text below)
Prior approval opinions of independent directors on matters related to the 12th meeting of the Fourth Board of directors
4、 Prior approval opinions on related party transactions between wholly-owned subsidiaries and actual controllers
We believe that this transaction of the company follows the principles of fairness, impartiality and openness, and the final transaction price is determined through negotiation based on the fair market price, without damaging the interests of the company and minority shareholders. The related party transaction complies with the provisions of relevant laws, regulations and the articles of association. It is agreed that the company will submit this proposal to the board of directors for deliberation and disclose it in accordance with the provisions.
(no text below)
Prior approval opinions of independent directors on matters related to the 12th meeting of the Fourth Board of directors
(there is no text on this page, which is the signature page of Jiangsu Chinagreen Biological Technology Co.Ltd(300970) independent directors’ prior approval opinions on matters related to the 12th meeting of the 4th board of directors) independent directors:
Wu Xiaoping, Li Zhengming, Xie Nan
April 8, 2022 (no text below)
